Global Sturge-Weber Syndrome Treatment Market, By Types (Type1, Type 2 and Type 3), Treatment (Medication, Laser Treatment and Surgery), Route of Administration (Oral, Parenteral and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2030.
Sturge-Weber Syndrome Treatment Market Analysis and Size
As per the National Organization for Rare Disorders, there is 1 case of the disease in 20,000–50,000 live births. Port-wine birthmarks are present in around 3 out of every 1,000 new-born, almost 6% of people with a port-wine birthmark on their face experience neurological issues. Expected introduction of numerous novel emerging drugs and the wide availability of advantageous reimbursement policies are anticipated to have beneficial effects.
Data Bridge Market Research analyses a growth rate in the Sturge-Weber syndrome treatment market in the forecast period 2023-2030. The expected CAGR of Sturge-Weber syndrome market is tend to be around 6% in the mentioned forecast period. The market was valued at USD 163.12 million in 2022, and it would grow up to USD 260 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Sturge-Weber Syndrome Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Types (Type1, Type 2 and Type 3), Treatment (Medication, Laser Treatment and Surgery), Route of Administration (Oral, Parenteral and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
GSK Plc. (U.K.), Bayer AG (Germany), Novartis AG (Switzerland), ALEVA NEUROTHERAPEUTICS (Switzerland), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Pfizer Inc. (U.S.), Johnson & Johnson Services, Inc. (India), Dr. Reddy’s Laboratories Ltd.(India), Mylan N.V. (U.S.), Qlaris Bio, Inc.(U.K.), Jazz Pharmaceuticals, Inc (U.K.), UCB S.A (Belgium)
|
|
Market Opportunities
|
|
Market Definition
Sturge-Weber syndrome is a type of neurological disorder that is present since birth. Babies suffering from the syndrome are born with a birthmark on their face known as a port-wine stain. A huge number of patients with Sturge-Weber Syndrome also suffer from seizures or convulsions. The other clinical features of this syndrome include glaucoma, paralysis and others.
Sturge-Weber Syndrome Treatment Market Dynamics
Drivers
- Growing Prevalence Of Sturge-Weber Syndrome
As per the Sturge Weber Syndrome Foundation, almost every person experience syndrome's onset equally often. In 3 infants out of 1,000, a port wine birthmark develops. The probablility of developing this syndrome is only between 8% and 15 % who have a face port-wine birthmark. The chances of sturge weber syndrome increases to 25% when one-half of the face is extremely affected, and when both sides of the face are affected, the risk increases to 33%. Thus, this increasing incidence boost the treatment market.
Opportunities
- Growing Number Of Research And Development Activities
Several projected introduction of several novel emerging drugs and availability of advantageous reimbursement policies are anticipated to have beneficial effects. Other factors that lead to the market expansion includes increased government funding for R&D and improved regulatory environment for the healthcare sector. Many technological advancements and increased investments in R&D activities have led to the discovery of numerous novel treatment options. Several new trends, such as companies concentrating on increase in R&D spending on numerous neurological disorders to develop novel medicines for treatment of sturge weber syndrome. Only about 22 clinical trials for molecules are now ongoing, which is a very low number. Furthermore, several clinical trials are conducted on many compounds; among these, one such trial, which is now in phase 1-2, is evaluating the use of mechanistic target of rapamycin inhibitors for treatment of PWB and medically resistant seizures in sturge-weber syndrome.
Restraints/Challenges
- High Cost of Treatment
The huge expenditure required for the surgeries and treatment processes hinders the market growth. Numerous market players make huge investments in manufacturing new and advanced treatment procedures to improve the recovery process, and in return, the cost is increased.
This Sturge-Weber syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Sturge-Weber syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Sturge-Weber Syndrome Treatment Market Scope
The Sturge-Weber syndrome treatment market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Type1
- Type 2
- Type 3
Treatment
- Medication
- Laser Treatment
- Surgery
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Sturge-Weber Syndrome Treatment Regional Analysis/Insights
The Sturge-Weber syndrome treatment market is analyzed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the Sturge-Weber syndrome treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market in the forecast period due to the presence of key manufacturers of the product is high and, increasing research and development activities.
Asia-Pacific is considered to grow over the coming years due to increasing awareness among the people. Furthermore, countries such as India, China, Japan are contributing to the immense market growth because of the supportive funds and initiatives by the government.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Sturge-Weber Syndrome Treatment Share Analysis
The Sturge-Weber syndrome treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Sturge-Weber syndrome treatment market
Key players operating in the Sturge-Weber syndrome treatment market include:
- GSK Plc. (U.K.)
- Bayer AG (Germany)
- Novartis AG (Switzerland)
- ALEVA NEUROTHERAPEUTICS (Switzerland)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited (Japan)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
- Pfizer Inc. (U.S.)
- Johnson & Johnson Services, Inc. (India)
- Dr. Reddy’s Laboratories Ltd. (India)
- Mylan N.V. (U.S.)
- Qlaris Bio, Inc. (U.K.)
- Jazz Pharmaceuticals, Inc (U.K.)
- UCB S.A (Belgium)
SKU-